Alcohol Biomarker Workshop Part 1. Overview of current and coming alcohol biomarkers

Alcohol Biomarker Update Workshop featuring:
Dr. Judy Hahn, UCSF
Q & A Session

GOALS of the Workshop
Learn about current Alcohol Biomarkers options for research.
Be introduced to New Alcohol Biomarkers in development.
Learn about in-the-field “Use Cases” of Transdermal Biosensors, Urine Alcohol
Metabolites, and Remote Blood Collection for PEth.
Discuss and get your Alcohol Biomarker questions answered.

SCHEDULE
Hour 3 -Discussion and Questions and Answers

Be sure to like, share, and subscribe.

Judy Hahn, Ph.D. is a Professor of Medicine in the HIV, ID, and Global Medicine Division in the Department of Medicine at the University of California, San Francisco. She is an epidemiologist with extensive experience studying the behavioral and biological intersections of substance use and infectious diseases. She leads multiple National Institutes of Health (NIH)-funded studies to reduce the harmful impact of alcohol use on HIV outcomes, primarily in east Africa. She was among the first HIV/alcohol researchers to use phosphatidylethanol (PEth) in her research, as well as ethyl glucuronide (EtG) and alcohol biosensors, for objective measurement for alcohol use in observational and intervention research. She has authored or co-authored over 150 manuscripts and is the Principal Investigator of multi-site studies of providing therapy to prevent tuberculosis (TB) disease among persons living with HIV who engage in heavy alcohol use Uganda, as well as randomized controlled trials (RCT) to examine the efficacy of behavioral interventions to reduce alcohol consumption in this population. Dr. Hahn is a committed teacher and mentor, directs courses on grant-writing, and conducts one-on-one mentoring of scholars at all levels of academia.

Julianne Jett, Ph.D. is a Postdoctoral Research Associate in the Elson S. Floyd College of Medicine at Washington State University. She received her doctorate in neuroscience and pharmacology from the University of Texas Health San Antonio. Her research used preclinical models to investigate how prolonged stress exposure changes brain function and induces cognitive impairments associated with depression and anxiety disorders. Her current research efforts investigate whether biomarkers and cognitive impairments associated with serious mental illness and substance use disorders can be used as diagnostic tools or predictors of treatment outcomes in clinical settings.

Yan Wang, Ph.D., MS is an Assistant Professor of Epidemiology. Dr. Wang received her MS and Ph.D. in Child and Family Studies from Syracuse University in 2013. She joined the Department of Epidemiology as a postdoctoral research associate in 2014 and was recruited by the department as a faculty member in 2016. With an interdisciplinary perspective, her research interests focus on leveraging advanced technologies and methods (e.g., wearable sensors, ecological momentary assessment/EMA) to improve the understanding of etiology and consequences of substance use (e.g., alcohol, medical marijuana). Dr. Wang is also a core faculty member of the Southern HIV and Alcohol Research Consortium (SHARC, U24 AA022002), which focuses on improving health among persons living with HIV in Florida. She also serves as the clinical core lead of the Consortium for Medical Marijuana Clinical Outcomes Research, which is a new consortium established in 2019 by the Florida Statute to provide infrastructural support for statewide research on medical marijuana and its clinical outcomes. Her current NIAAA-funded project (R21 AA027191) aims to validate a newly developed wrist-worn alcohol biosensor (BACtrack Skyn) in both laboratory and real-life settings and examine whether the biosensor works equivalently for persons living with or without HIV.

Recorded Wednesday, March 2nd, 2022.